Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N- acetylcysteine Klaus-Jürgen Gutleben, Jörg Eller, Jessica Vöckler, Margot.

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Approach to diagnosis of infective endocarditis

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria M.J. Rybak Clinical Microbiology and Infection

Herpes zoster in non-hospitalized children

In vitro activity of cefpirome and vancomycin in combination against gentamicin- susceptible and gentamicin-resistant Staphylococcus aureus A. Carricajo,

Hydatid disease Clinical Microbiology and Infection

Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data M.

Link between intracellular pathogens and cardiovascular diseases

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Alasdair P. MacGowan, Caroline Rynn, Mandy Wootton, Karen E. Bowker, H

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

Inga Odenholt, Elisabeth Löwdin, Otto Cars

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach,

Cephalosporins: a pharmacological update

Retrospective study of CMV retinitis in patients with AIDS

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants Maria-Cristina Negri,

Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria Inga Odenholt, Elisabeth Löwdin,

Sepsis and neutropenia induced by clozapine

A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics J. Moira Greenhalgh,

Uncommon opportunistic fungi: new nosocomial threats

Elements of design: the knowledge on which we build

Evidence for a true post-β-lactamase-inhibitor effect of clavulanic acid against Klebsiella pneumoniae and Haemophilus influenzae V. Murbach, N. Dhoyen,

André Bryskier Clinical Microbiology and Infection

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

B. Sádaba, J.R. Azanza, M.A. Campanero, E. García-Quetglas

Laboratory diagnosis of Clostridium difficile disease

W.A. Craig Clinical Microbiology and Infection

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease Inge O. Baas, G. Johan A. Offerhaus, Ralph.

Pathogenesis of catheter-related infections: lessons for new designs

T.M. File Clinical Microbiology and Infection

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Antibacterial drug discovery in the 21st century

Community-acquired pneumonia: epidemiologic and clinical consideration

Abstracts cont. Clinical Microbiology and Infection

Clinical infection services—the Leiden experience

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

Granulocyte colony-stimulating factor (G-CSF) and interleukin (IL)-8 in sera from patients with Staphylococcus aureus septicemia Bo Söderquist, Dan Danielsson,

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study R. Goering, C.-E. Nord, R.

In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† C.B. Moore,

G.C. Schito Clinical Microbiology and Infection

J.A. Pérez-Molina, F. Fernández Clinical Microbiology and Infection

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Vincent Calvez, Marc Grandadam Clinical Microbiology and Infection

Presentation transcript:

Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent injection Hassan Elkhaïli, Jean-Daniel Peter, Davide Pompei, Dominique Levěque, Laurence Linger, Yves Salmon, Julie Salmon, Henri Monteil, François Jehl Clinical Microbiology and Infection Volume 4, Issue 1, Pages 18-26 (January 1998) DOI: 10.1111/j.1469-0691.1998.tb00329.x Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Relationship between ISB (see text) and meropenem concentrations for E. cloacae after 4 h of contact. Clinical Microbiology and Infection 1998 4, 18-26DOI: (10.1111/j.1469-0691.1998.tb00329.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Bactericidal activity against E. cloacae (6-h exposure) of micropig serum diluted to 1/2 versus time profiles following administration of meropenem by intravenous short infusion and continuous infusion. Clinical Microbiology and Infection 1998 4, 18-26DOI: (10.1111/j.1469-0691.1998.tb00329.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Bactericidal activity against K. pneumoniae (6 h exposure) of micropig serum diluted to 1/2 versus time profiles following administration of meropenem by intravenous short infusion and continuous infusion. Clinical Microbiology and Infection 1998 4, 18-26DOI: (10.1111/j.1469-0691.1998.tb00329.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Relationship between ISB and cefpirome concentrations for S. aureus after 4 h (A) and 8 h (B) of contact. Clinical Microbiology and Infection 1998 4, 18-26DOI: (10.1111/j.1469-0691.1998.tb00329.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 5 Relationship between ISB and cefpirome concentrations for E. cloacae after 6 h of contact. Clinical Microbiology and Infection 1998 4, 18-26DOI: (10.1111/j.1469-0691.1998.tb00329.x) Copyright © 1998 European Society of Clinical Infectious Diseases Terms and Conditions